EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSBTAG00000017103
Gene Symbol: MAP3K13
5 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSBTAG00000009065
Gene Symbol: MAP3K5
4 Enzyme and pathways 5 Cross references
220 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSBTAG00000011600
Gene Symbol: MAP3K8
29 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSBTAG00000005700
Gene Symbol: MAP3K9
5 Cross references
207 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSBTAG00000016206
Gene Symbol: MAOA
15 Enzyme and pathways 5 Cross references
159 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSBTAG00000001288
Gene Symbol: MAOB
5 Enzyme and pathways 5 Cross references
345 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSBTAG00000018248
Gene Symbol: MGLL
13 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSBTAG00000010475
Gene Symbol: MLNR
7 Enzyme and pathways 5 Cross references
175 Possible Orthologues:

Multidrug Resistance Protein 1

Ensembl ID : ENSBTAG00000015666
Gene Symbol: LOC100296627
4 Cross references
188 Possible Orthologues:

Multidrug Resistance Protein 1

Ensembl ID : ENSBTAG00000005997
Gene Symbol: ABCB1
5 Enzyme and pathways 4 Cross references
188 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSBTAG00000011616
Gene Symbol: MPO
5 Enzyme and pathways 5 Cross references
193 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSBTAG00000006234
Gene Symbol: NPR1
3 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).